FDA approves new indication for Vemlidy

The United States Food and Drug Administration (FDA) has approved the Supplemental New Drug Application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic HIV infection. hepatitis B (HBV) in pediatric patients aged 12 years and elderly with compensated liver disease.

Developed and marketed by our leading biotechnology company Gilead Sciences (Nasdaq: GILD), Vemlidy has already obtained FDA approval for the treatment of adults with this…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

About Michael Bill

Check Also

Varadkar says there is no indication the tech giants will close Irish offices

Leo Varadkar said the government has asked IDA Ireland and Enterprise Ireland to step up …